Next level diagnostics

About Proteomedix

Proteomedix was founded in 2010 as a spin-off company of ETH Zurich to bring together the exceptional and specific expertise of a multi-disciplinary group of the world’s leading scientists and clinicians. As a medical need-oriented organization with a strong focus on research and development, it relies on a powerful network of clinicians, IVD experts, pharmacists and marketers. Proteomedix is located at the Bio-Technopark in Zurich, Switzerland.

From lab to clinic

Disrupted biological signaling pathways can lead to cancer. Proteomedix develops highly selective and targeted biomarkers by analyzing and understanding the specific signaling pathways. While the latest mass spectrometry-based proteomics technology was used during the research phase to identify the protein biomarkers, our final tests are immunoassay-based. This offers a rapid, sensitive, reproducible, cost effective and easily manageable analysis. The reagents used are stable and the method is established in routine diagnostic laboratories to guarantee wide application of our first test, Proclarix.

What to expect next

After its maiden product, the Proclarix test for improving prostate cancer diagnosis, Proteomedix is now developing additional products for prostate cancer prognosis and patient selection to enable precision medicine.